We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon
Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Would suggest all listen to the UBS presentation this morning. The project announced for the funding being done by the French government is important..........listen to Willard's explanation, plus the 'promised' two new projects this Q and next Q.
One has to appreciate Willard's constant reminder of the 'shareholders' in the company plans. Sort of novel to have a CEO being concerned about the investors. (:>)
Q report is now on schedule for Friday of this week. The key will be whether they can continue to build their cash position. From the 1Q to the 2Q they increased cash from $39.1 million to $45.0 Million, so with several previously announced deals being booked during the 3rdQ it will be important to see if they can continue to keep cost down and build their cash reserves. Stock has bounced with PFE deal announcement today, but volume is only average........so appears new money coming in will be keyed to Q report.
My guess is that they figured this would be the quickest venue to get another drug approved.......guess they didn't remember the result of Coreg and the huge market they garnered for that one. Appears that FLML and ELN are both working on this method of drug delivery......leaving me to question why I still own shares in these two. I still believe that reformulation for existing drugs will eventually be successful.....but when???? (:<)